Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William A Freed-Pastor

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Cell Cycle (Georgetown, Tex.)|December 1, 2011
Dissimilar DNA binding by p53 in normal and tumor-derived cellsWilliam A Freed-Pastor, Carol Prives
Genes & Development|June 21, 2012
Mutant p53: one name, many proteinsWilliam A Freed-Pastor, Carol Prives
Cancer Cell|September 13, 2022
Getting a handle on KRAS inhibitor resistance with hapten-mediated anti-tumor immunityWilliam A Freed-Pastor, Andrew J Aguirre
The Journal of Biological Chemistry|August 24, 2007
Stability of checkpoint kinase 2 is regulated via phosphorylation at serine 456Elizabeth M Kass, Jinwoo Ahn, Tomoaki Tanaka, et al.
Cell Reports|June 15, 2017
Quantitative Analysis of the DNA Methylation Sensitivity of Transcription Factor ComplexesJudith F Kribelbauer, Oleg Laptenko, Siying Chen, et al.
Cancers|December 23, 2022
Emerging Role of Targeted Therapy in Metastatic Pancreatic AdenocarcinomaBrandon M Huffman, Haley Ellis, Alexander C Jordan, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 4, 2018
Accurate and sensitive quantification of protein-DNA binding affinityChaitanya Rastogi, H Tomas Rube, Judith F Kribelbauer, et al.
Genes & Development|June 18, 2015
Mutant p53 cooperates with the SWI/SNF chromatin remodeling complex to regulate VEGFR2 in breast cancer cellsNeil T Pfister, Vitalay Fomin, Kausik Regunath, et al.
Cell|January 24, 2012
Mutant p53 disrupts mammary tissue architecture via the mevalonate pathwayWilliam A Freed-Pastor, Hideaki Mizuno, Xi Zhao, et al.
Nature|June 15, 2022
Deciphering the immunopeptidome in vivo reveals new tumour antigensAlex M Jaeger, Lauren E Stopfer, Ryuhjin Ahn, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Cell Cycle (Georgetown, Tex.)|December 1, 2011
Dissimilar DNA binding by p53 in normal and tumor-derived cellsWilliam A Freed-Pastor, Carol Prives
Genes & Development|June 21, 2012
Mutant p53: one name, many proteinsWilliam A Freed-Pastor, Carol Prives
Cancer Cell|September 13, 2022
Getting a handle on KRAS inhibitor resistance with hapten-mediated anti-tumor immunityWilliam A Freed-Pastor, Andrew J Aguirre
The Journal of Biological Chemistry|August 24, 2007
Stability of checkpoint kinase 2 is regulated via phosphorylation at serine 456Elizabeth M Kass, Jinwoo Ahn, Tomoaki Tanaka, et al.
Cell Reports|June 15, 2017
Quantitative Analysis of the DNA Methylation Sensitivity of Transcription Factor ComplexesJudith F Kribelbauer, Oleg Laptenko, Siying Chen, et al.
Cancers|December 23, 2022
Emerging Role of Targeted Therapy in Metastatic Pancreatic AdenocarcinomaBrandon M Huffman, Haley Ellis, Alexander C Jordan, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 4, 2018
Accurate and sensitive quantification of protein-DNA binding affinityChaitanya Rastogi, H Tomas Rube, Judith F Kribelbauer, et al.
Genes & Development|June 18, 2015
Mutant p53 cooperates with the SWI/SNF chromatin remodeling complex to regulate VEGFR2 in breast cancer cellsNeil T Pfister, Vitalay Fomin, Kausik Regunath, et al.
Cell|January 24, 2012
Mutant p53 disrupts mammary tissue architecture via the mevalonate pathwayWilliam A Freed-Pastor, Hideaki Mizuno, Xi Zhao, et al.
Nature|June 15, 2022
Deciphering the immunopeptidome in vivo reveals new tumour antigensAlex M Jaeger, Lauren E Stopfer, Ryuhjin Ahn, et al.
Pageof 2